Two experts see major challenges facing the adoption of Novo Nordisk and Eli Lilly’s obesity drugs.
Recent Posts
- This country may have the fastest-growing e-commerce sector ‘on the planet’
- What tariffs mean for car prices: ‘There’s no such thing as a 100% American vehicle,’ auto expert says
- How the Federal Reserve’s rate policy affects mortgages
- Government shutdown: House to vote on last-minute funding bill without debt limit hike
- The Fed cut interest rates, but mortgage costs jumped. Here’s why